400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Investor Presentation
Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Reports First Quarter 2026 Financial Results
2026 Annual Meeting of Stockholders - Election of Four Class II Directors
Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
Annual Report to Security Holders
Announces Appointment of John D. Fowler, Jr. to Board of Directors
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
S-8 POS
Definitive Revised Proxy Statement